Industry News & Literature
Stay ahead with expert-curated flow cytometry & cell/gene therapy news, landmark publications (including OMICs),
and fresh open-access research — all centralized to save you hours every week.
Featured Industry News
Handpicked headlines in flow cytometry & cell/gene therapy. Non-members see a preview; members get the full feed.
July 6, 2026 – Flow Cytometry
Waters Biosciences Outlines Its Post-Merger Strategy for Spectral Flow Cytometry
• FACSDiscover A7 remains targeted for a 2026 commercial launch
• Waters is emphasizing cross-instrument and cross-laboratory standardization
• A reported 60-color panel demonstrates continued expansion of spectral cytometry
• Imaging, sorting, analysis, and multiomics are being positioned as an integrated workflow
July 20, 2026 – Flow Cytometry
Researchers Publish a 27-Color Panel for Standard Three-Laser Spectral Cytometers
• The panel provides 27-color analysis using a standard three-laser system
• Sixteen immune and nonimmune populations can be evaluated
• Performance was examined across several biologically distinct murine tissues
• The work may lower the instrument barrier to high-dimensional spectral cytometry
July 20, 2026 – Flow Cytometry
ARUP Laboratories Launches a Clinical Spectral Flow Cytometry Assay for Myeloma MRD
• ARUP introduced an 18-marker, single-tube spectral-flow MRD assay
• The assay requires less specimen than many conventional multi-tube approaches
• ARUP reports detection of 14 abnormal cells among five million analyzed cells
• The launch is a major step toward routine clinical adoption of spectral cytometry
July 1, 2026 – CGT
FDA Expands Casgevy Approval to Children as Young as Two Years Old
• Casgevy is now approved for eligible patients two years of age and older
• The decision broadens access to the first approved CRISPR-based therapy
• Pediatric treatment may reduce the accumulation of irreversible disease complications
• Manufacturing, conditioning, reimbursement, and specialized-center capacity remain challenges
July 29, 2026 – CGT
Johnson & Johnson Makes a Multibillion-Dollar Bet on In Vivo CAR-T Therapy
• Johnson & Johnson and Sail will develop in vivo CAR-T therapies
• The transaction includes substantial equity, milestone, and acquisition-option value
• The initial therapeutic focus includes autoimmune and immune-mediated diseases
• In vivo programming could reduce reliance on patient-specific ex vivo manufacturing
Source: https://www.biospace.com/press-releases/bioaffinity-technologies-announces-initiation-of-large-scale-longitudinalclinical-study-for-its-noninvasive-cypath-lung-cancer-diagnostic
August 3, 2026 – CGT
Rocket Pharmaceuticals Reports Early Safety Progress for Danon Disease Gene Therapy
• Three patients were treated under a modified Phase 2 protocol
• No thrombotic microangiopathy or capillary-leak syndrome had been reported at announcement
• The protocol includes a recalibrated dose and expanded immunomodulation
• The findings are encouraging but remain early, sponsor-reported, and limited in scale
Curated Literature Highlights
2020-07-15 – Cytometry Part A
OMIP-069: 40-Color Full-Spectrum Flow Cytometry Panel for Deep Immunophenotyping of Major Cell Subsets of the Human Peripheral Blood
What it is: A community-adopted, 40-color spectral panel and workflow that unlocked routine, high-parameter immunophenotyping on full-spectrum instruments.
Why landmark (metrics): Cited well over 100 times (PubMed shows “Cited by” >300); method has become a go-to reference for building large spectral panels across core facilities.
2021-12-02 – Blood
2021 Update on MRD in Acute Myeloid Leukemia: A Consensus Document From the European LeukemiaNet MRD Working Party
What it is: The global standard-setting MRD guideline integrating flow cytometry (and molecular) with thresholds, time points, and reporting rules used in trials and clinical care.
Why landmark (metrics): Cited >600 times and directly drives assay design/interpretation and clinical decisions worldwide; widely implemented by hospital and reference labs.
2021-09-20 – Cytometry Part A
Full Spectrum Flow Cytometry as a Powerful Technology for Cancer Immunotherapy Research
What it is: A practice-oriented review that codified best practices for spectral instrumentation, panel design, unmixing, and analysis in immuno-oncology.
Why landmark (metrics): Cited ~110 times; catalyzed rapid adoption of spectral cytometry across IO programs and cores by providing a clear, implementable playbook.
How SuperNova Flow Cytometry Saves You Time
No more endless PubMed searches or scattered Google alerts —
our curated hub saves hours every week, so you can focus on discovery and innovation.
Save Hours
Members cut down research time by accessing centralized news and peer-reviewed literature.
Stay Focused
Skip irrelevant updates — our expert curation highlights only what impacts your work.
.
Trusted Sources
Every article comes from leading journals, conferences, and open-access databases.
.
Your Competitive Edge in Flow Cytometry & CGT
Join SuperNova Flow Cytometry to access curated industry news, landmark publications, and member-only resources —
all designed to save you time and keep you ahead of the curve.
ASCP- and ASC-accredited CMLE credits included with every accredited-course.